NHS England South West

Subject: Specialised Services Circular (SSC)
Sent on behalf of: Chair of the SW Specialised Service Circular Group

Dear Colleagues,

Please find attached the following Specialised Services Circular(s):

SSC Number	SSC Title	Trusts approved to prescribe in accordance with the SSC, providing appropriate internal governance arrangements are in place
2867	**NHS England Clinical Commissioning Policy: Icatibant for treatment of moderate to severe acute swellings due to bradykinin-mediated angioedema with normal C1 inhibitor (adults) [2315]**	North Bristol Trust University Hospitals Bristol and Weston Foundation Trust University Hospitals Plymouth Trust

Is an implementation plan required from all SW trusts (regardless of commissioned status) for this SSC? No

For all other South West region trusts this is for information only.

Trusts should ensure that use is registered on the Blueteq system (if appropriate).

Treatment will only be funded where the drugs minimum dataset is fully and accurately populated.

Please direct any queries to: england.speccomm-southwest@nhs.net

All Chief Executives

All Medical Directors

All Chief Pharmacists

Specialised Commissioning South West
NHS England
100 Temple Street
Bristol
BS1 6AG
Email: england.speccomm-southwest@nhs.net

8 August 2025

Dear Colleagues,

Re: NHS England Clinical Commissioning Policy: Icatibant for treatment of moderate to severe acute swellings due to bradykinin-mediated angioedema with normal C1 inhibitor (adults) [2315]

I am writing to advise you regarding the funding position on the recently published NHS England Clinical Commissioning Policy (CCP) for the use of icatibant for treatment of moderate to severe acute swellings due to bradykinin-mediated angioedema with normal C1 inhibitor (adults).

The CCP can be found at: [NHS England » Icatibant for treatment of moderate to severe acute swellings due to bradykinin-mediated angioedema with normal C1 inhibitor]

Icatibant will be routinely commissioned from [31st July in line with the CCP].

In addition, NHS England will commission icatibant in children where icatibant is used in accordance with the NHS England policy 'Commissioning medicines for children in specialised services' for younger patients in accordance with the icatibant dosage as described in the BNF for Children. In this setting icatibant should only be requested by and administered in specialised treatment centres and the use of icatibant should be discussed at a multi-disciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area. Separate Blueteq registration forms for registration of adults and children have been made available. It should also be noted that icatibant should be used within the Trust's governance framework as icatibant is not licensed for use in children.

In addition:

- Trusts must ensure that only invoices for the drug procurement costs of icatibant in this indication are invoiced to NHSE and that they are also submitting complete and accurate information via the high-cost drugs minimum dataset (MDS). All other on costs are in block arrangements.
- In line with the terms and conditions included in the NHS Standard Contract, Schedule 6a Reporting Requirements for drugs will apply. Payment of Trust invoices will be contingent on the completion of the MDS record and this information

being made available in a timely way.

- Patients must be registered via Blueteq (initiation form) and meet the clinical criteria on the registration form. This letter gives the required one month's notice as per Schedule 2 Part G (Other Local Agreements, Policies and Procedures) of your Specialised Services contract for prior approval for this treatment/indication. From one month of the date specified above, NHS England will only reimburse these treatments for patients that have been confirmed as meeting the eligibility criteria via the formal Prior Approval Scheme (i.e. Blueteq). You may wish to use the prior approval mechanism earlier than this to expedite access to this drug.
- **Payment of Trust invoices will be contingent on Blueteq registration and MDS record applicable to the drug being completed and this information being made available in a timely way. Please note there are different Blueteq registration forms for adults and children.**
- Trusts must ensure that local governance aspects (e.g. technical issues, education & training, patient information) have been identified and addressed for all staff groups (as appropriate) in order to permit the safe delivery of this therapy.

I would be grateful if you could cascade this information to relevant clinical teams within your organisation to support the consistent adoption of the policy nationally.

With best wishes,



Emma Redfern
Medical Director NHS England South West Region

Tracey Williams
Principal Pharmacist